Overview

A Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of extended dosing with ION-682884 in participants with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).
Phase:
Phase 3
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.